Why direct-to-consumer telehealth brands fail on the landing page

A direct-to-consumer brand and a telehealth clinic can run the same clinical model and get very different reviews, because they present very differently. The clinic has one site, a clear clinical identity and a small marketing surface. The brand has a paid funnel, a quiz, three landing page variants, an affiliate offer and a shop, and a certification reviewer reads all of it.

The surface is bigger than you think

Ask a brand to list its domains and you get the main one. Ask engineering and you get the main one, the two landing domains the media buyer registered, the staging domain that is publicly reachable, the shortlink domain, and the legacy brand from the pivot two years ago that still resolves.

Every one of those matters, for two separate reasons. Certification attaches to a website, so the ones that take intake, present prices or transact need certifying, and that decides what the exercise actually costs. And the ones that do not need certifying still need disclosing, because being found to operate a domain you did not mention is a credibility problem across the whole file.

Consolidating before you apply is nearly always cheaper than certifying everything, and it is a decision that stops being available once applications are filed.

The quiz is a clinical artefact

Most direct-to-consumer telehealth funnels open with a quiz. Marketing treats it as a conversion mechanism. A reviewer treats it as the beginning of the clinical encounter, and reads it accordingly.

The questions that matter: does the quiz tell the patient what it is for, does it avoid promising an outcome or a specific prescription, does it screen for the contraindications the model requires, and is it honest that a prescriber may decline?

The failure pattern is a quiz that implies the medicine is already decided. Copy like "find your dose" before a prescriber has seen anything describes a model where the clinical decision is a formality, which is precisely the model the certification exists to screen out. It is also usually not what the business actually does, which makes it an expensive way to be misread.

Variants, and the page nobody reviewed

Direct-to-consumer teams ship page variants continuously. That is the job. It is also the mechanism by which a certified brand ends up with an uncertified claim live on a page receiving traffic.

Two habits fix most of this:

• A claims allowlist. A short document that says what may be said about each product and, more usefully, what may not. Written once against the actual product, approved by whoever owns clinical, and given to every copywriter and every agency.
• A single review gate before a page goes live. Not a committee. One person who reads new landing copy against the allowlist.

Brands that do this ship faster than brands that do not, because the alternative is a legal review of every page by somebody who has to reconstruct the reasoning from scratch each time.

Social proof is claim material

Testimonials, before-and-after imagery, star ratings and influencer content all make claims, and the reviewer reads them as claims regardless of who wrote them.

A patient testimonial that states a result is a results claim. An affiliate's video comparing a compounded preparation to the brand-name drug is a comparison claim, and it is on your funnel. Content you did not write but did distribute is content you are answerable for, and affiliates are covered in marketplace and affiliate access.

The subscription mechanics are reviewed too

Direct-to-consumer telehealth is mostly subscription telehealth, and the subscription is scrutinised from several directions at once: certification review, card network rules on recurring billing, and consumer protection attention on negative option marketing.

What is expected is not onerous. Disclose the renewal terms where the purchase happens rather than in a footer. Make cancellation available through the same channel as sign-up. Say what happens if a prescriber declines and whether the patient is charged. Put a recognisable descriptor on the card statement.

Each of those also reduces chargebacks, which matters independently because chargeback exposure is part of what your acquirer is underwriting.

Who owns this after approval

The structural problem for brands specifically is that certification is usually run by whoever handled the processor conversation, and the pages that put the certification at risk are shipped by a marketing team that was never told the rules apply to them.

Name an owner, give them the allowlist, and put them in the path of new landing pages. That single piece of process is worth more than anything else on this list, because it is what makes the certification survive the six months after it is granted.

Before you file

Three things, in order. Get the complete domain list, from the registrar account rather than from memory. Write the claims allowlist against what your product actually is. Then read every page a patient can reach against it, including the variants that are still live.

That is most of the preparation work, and doing it first is the difference between a review with no questions and a rework loop.

What belongs in a claims allowlist

Brands ask what the document should actually contain, so here is the shape that works. One page per product, and it is written for a copywriter rather than for a lawyer.

• What the product is, in one sentence, including whether it is compounded and who prepares it.
• The approved phrasing for the two or three things everybody wants to say, quoted exactly so it can be pasted rather than paraphrased.
• The prohibited phrasing, quoted just as exactly, because a list of concepts gets reinterpreted and a list of sentences does not.
• Who to ask when a new angle comes up, with a commitment to answer within a day, because a reviewer who takes a week gets routed around.
• The date it was last checked against the product and the pharmacy relationship, since both change.

The quiet risk in a growing brand

The claims problem is rarely introduced by the person who understands the rules. It is introduced six months later by a new agency, a freelance copywriter, an affiliate or a support agent writing a reassuring reply to a nervous customer.

Every one of those is a channel where your product gets described by somebody who never read the allowlist. Which means distribution of the document matters as much as its content: onboarding for agencies, a clause in affiliate terms, a line in the support macro library, and a review step before a new landing page goes live.

Brands that treat the allowlist as an artefact to be distributed keep their certification quietly. Brands that treat it as a one-off compliance exercise rediscover the problem during monitoring.